Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • The Pharma 50

Cost of COVID-19 vaccine nationalism could hit $1.2 trillion

By Brian Buntz | October 28, 2020

COVID-19 coronavirus

[Photo by Fusion Medical Animation on Unsplash]

Rand Europe, WHO and the president of Germany recently warned against vaccine nationalism.

The cost of nationalistic tendencies to hoard vaccines and prioritize vaccines for their citizenry could lead to a global reduction in gross domestic product of $1.2 trillion, according to the nonprofit think tank Rand Europe. By contrast, the global economic penalty of failing to develop a COVID-19 vaccine would be $3.4 trillion, according to the organization.

The think tank reasoned that the inability to control the virus internationally would extend its economic toll on various economic sectors.

WHO head Tedros Adhanom Ghebreyesus also warned on Oct. 25 that countries that focus vaccine efforts on their citizens could ultimately prolong the pandemic. The world should aim to “vaccinate some people in all countries rather than all people in some countries,” Ghebreyesus said in a virtual conference at the World Health Summit in Berlin.

German President Frank-Walter Steinmeier echoed that sentiment at the World Health Summit in Berlin. COVID-19 is “indifferent to the nationality of its victims. It will continue to overcome every barrier in the future if we do not confront it together,” he said.

Rand Europe concluded that even denying equal access to the vaccine to developing countries could have a global cost of $153 billion a year in GDP terms.

Meanwhile, providing vaccines to lower-income countries would cost an estimated $25 billion.

Rand Europe concluded that the return for every $1 high-income countries invest in distributing vaccines to low-income nations would be $4.8.

“Our findings suggest that there are real economic incentives for the higher income countries to drive vaccine development and distribution to ensure that the rest of the world has access to vaccines as soon as possible,” wrote Marco Hafner or Rand Europe, who was the study’s lead author.

 


Filed Under: Drug Discovery
Tagged With: covid-19, RAND Europe, vaccine, WHO
 

Tell Us What You Think! Cancel reply

You must be logged in to post a comment.

Related Articles Read More >

Lab facility
Massachusetts is competing for ARPA-H biomedical research center
Blockchain
Startup vies to get blockchain adoption in pharma off the ground
Black Diamond Therapeutics
Black Diamond analysis highlights 22 new oncogenic HER2 driver mutations
NIH National Institutes of Health
NIH licenses COVID-19 research technologies to WHO initiative

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Drug Discovery and Development
  • MASSDEVICE
  • DEVICETALKS
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • MEDTECH 100
  • Medical Design Sourcing
  • Subscribe to our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • The Pharma 50